A major breakthrough is the recent approval of a novel Smo antagonist Erivedge/Vismodegib (GDC-0449) in the Shh field by the FDA for treating metastatic BCC and locally advanced BCC deemed untreatable by surgery or radiation (Robarge et al., 2009). Here, SHH is linked to skin basal cell carcinoma.